Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA
12:55pm, Friday, 14'th Apr 2023
The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement
10:00am, Thursday, 13'th Apr 2023
INDIANAPOLIS , April 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also conduct a conference
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:57am, Tuesday, 11'th Apr 2023
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
3 Sector ETFs to Play as Recession Fears Are on the Rise
12:09pm, Monday, 10'th Apr 2023
With recession fears on the rise, look into some sectors that can shield from market volatility.
Manager Of Top T. Rowe Price Fund Is Still 'Pretty Cautious'
07:00am, Friday, 07'th Apr 2023
Looking for a go-anywhere stock fund that isn't trapped in a style box and can buy stocks of all sizes and styles? Well, Justin White's T.
Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study
10:21am, Wednesday, 05'th Apr 2023
Eli Lilly said a higher dose of the up-and-coming Alzheimer's treatment, remternetug, had a larger effect on clearing amyloid plaque.
2 Top Growth Stocks That Can Withstand an Economic Downturn
10:15am, Wednesday, 05'th Apr 2023
New data points to a looming recession in the U.S. In response, growth stocks took a step backward yesterday. Eli Lilly and Catalyst Pharmaceuticals are both capable of swimming against the current.
Why Lilly (LLY) Could Beat Earnings Estimates Again
01:42pm, Tuesday, 04'th Apr 2023
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:38am, Tuesday, 04'th Apr 2023
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Top Healthcare Stocks to Buy for April
09:12am, Tuesday, 04'th Apr 2023
Eli Lilly's promising diabetes drug Mounjaro could be an obesity-therapy blockbuster. Johnson & Johnson's consumer healthcare spinoff will make the company more profitable.
7 Spectacular Growth Stocks to Buy in April
06:52pm, Monday, 03'rd Apr 2023
Historically, investors looking for growth stocks to buy found the best opportunities during economic expansions, which generally coincided with lower interest rates. That was true of the most recent
3 Stocks That Could Benefit From the Ozempic Craze
09:45am, Thursday, 30'th Mar 2023
Novo Nordisk's business has been red-hot, thanks to soaring obesity-related revenue. Eli Lilly has its own promising weight-loss treatment which could be a game changer.
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
11:40pm, Wednesday, 29'th Mar 2023
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po
Final trades: Intel, JPMorgan, Eli Lilly & Amgen
07:17pm, Wednesday, 29'th Mar 2023
The final trades of the week. With CNBC's Tyler Mathisen and the Fast Money traders, Steve Grasso, Courtney Garcia, Tim Seymour and Guy Adami.
Drugs for obesity are a massive market, says Mizuho's Jared Holz
06:59pm, Wednesday, 29'th Mar 2023
Jared Holz, Mizuho, joins 'Fast Money' to discuss obesity drugs with CNBC's Tyler Mathisen and the Fast Money traders.
